Edition:
United Kingdom

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

0.89USD
16 Nov 2018
Change (% chg)

$0.01 (+0.69%)
Prev Close
$0.88
Open
$0.89
Day's High
$0.92
Day's Low
$0.89
Volume
2,388
Avg. Vol
24,004
52-wk High
$2.47
52-wk Low
$0.66

Latest Key Developments (Source: Significant Developments)

Capricor Therapeutics Inc Files For Mixed Shelf Of Upto $75 Mln
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $75 MILLION - SEC FILING.  Full Article

Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING.CAPRICOR THERAPEUTICS INC - ON DEC 20, LELAND GERSHELL GAVE NOTICE OF HIS RESIGNATION AS CHIEF FINANCIAL OFFICER OF COMPANY, EFFECTIVE JANUARY 1, 2018.  Full Article

Capricor & California Institute For Regenerative Medicine​ Entered Into Amendment 3 To CIRM Notice Loan Award
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR SAYS ‍ON DEC 11, CO, CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE​ ENTERED INTO AMENDMENT NO. 3 TO CIRM NOTICE OF LOAN AWARD - SEC FILING.CAPRICOR SAYS PURSUANT TO AMENDMENT, TOTAL LOAN BALANCE UNDER LOAN AWARD FORGIVEN BY CIRM, TERMINATING UNIT, CO'S OBLIGATION TO REPAY LOAN BALANCE​.CAPRICOR - ‍DECISION TO TERMINATE LOAN AWARD AND FORGIVE LOAN BALANCE WAS DUE TO ABANDONMENT OF ALLSTAR PROJECT AT END OF PROJECT PERIOD​.  Full Article

Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002.CAPRICOR THERAPEUTICS INC - POTENTIAL REGISTRATION TRIAL IN DUCHENNE MUSCULAR DYSTROPHY ON TRACK TO INITIATE IN Q1 OF 2018.CAPRICOR THERAPEUTICS-PLANS TO APPLY FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR CAP-1002 BASED ON UPDATED GUIDANCE RECENTLY ISSUED BY FDA.  Full Article

Capricor Therapeutics reports Q3 loss per share $0.12
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Capricor Therapeutics Inc ::Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program.Q3 loss per share $0.12.  Full Article